[go: up one dir, main page]

MX2017006464A - Combinaciones de inhibidor de tlr e inhibidor de tirosina cinasa de bruton. - Google Patents

Combinaciones de inhibidor de tlr e inhibidor de tirosina cinasa de bruton.

Info

Publication number
MX2017006464A
MX2017006464A MX2017006464A MX2017006464A MX2017006464A MX 2017006464 A MX2017006464 A MX 2017006464A MX 2017006464 A MX2017006464 A MX 2017006464A MX 2017006464 A MX2017006464 A MX 2017006464A MX 2017006464 A MX2017006464 A MX 2017006464A
Authority
MX
Mexico
Prior art keywords
inhibitor
bruton
tyrosine kinase
tlr
combinations
Prior art date
Application number
MX2017006464A
Other languages
English (en)
Inventor
Y Chang Betty
Kuo Hsu-Ping
Beaupre Darrin
Original Assignee
Pharmacyclics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Llc filed Critical Pharmacyclics Llc
Publication of MX2017006464A publication Critical patent/MX2017006464A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proveen composiciones y métodos para tratar neoplasias malignas de linfocitos B en un sujeto que lo necesita mediante la administración al sujeto de una cantidad terapéuticamente eficaz de una combinación que comprende un inhibidor de un inhibidor de BTK y un inhibidor de TLR.
MX2017006464A 2014-11-17 2015-11-17 Combinaciones de inhibidor de tlr e inhibidor de tirosina cinasa de bruton. MX2017006464A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462080921P 2014-11-17 2014-11-17
US201562127740P 2015-03-03 2015-03-03
PCT/US2015/061091 WO2016081460A1 (en) 2014-11-17 2015-11-17 Tlr inhibitor and bruton's tyrosine kinase inhibitor combinations

Publications (1)

Publication Number Publication Date
MX2017006464A true MX2017006464A (es) 2018-08-09

Family

ID=56014455

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006464A MX2017006464A (es) 2014-11-17 2015-11-17 Combinaciones de inhibidor de tlr e inhibidor de tirosina cinasa de bruton.

Country Status (11)

Country Link
US (1) US20170354655A1 (es)
EP (1) EP3220912A4 (es)
JP (1) JP2017533944A (es)
CN (1) CN106999495A (es)
AU (1) AU2015350136A1 (es)
BR (1) BR112017010262A2 (es)
CA (1) CA2966542A1 (es)
HK (1) HK1243929A1 (es)
MX (1) MX2017006464A (es)
TW (1) TW201628622A (es)
WO (1) WO2016081460A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2325171B1 (en) 2005-05-26 2013-10-09 Aldexa Therapeutics, Inc. Quinoline derivatives for treating retinal diseases
US9814701B2 (en) 2009-12-11 2017-11-14 Aldeyra Therapeutics, Inc. Compositions and methods for the treatment of macular degeneration
US20120087915A1 (en) 2010-06-03 2012-04-12 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
MX2015001081A (es) 2012-07-24 2015-10-14 Pharmacyclics Inc Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk).
CN105120866B (zh) 2013-01-23 2020-02-14 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
CN118724806A (zh) 2015-08-21 2024-10-01 奥尔德拉医疗公司 氘化化合物和其用途
US11040039B2 (en) 2017-10-10 2021-06-22 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
JP2021533154A (ja) 2018-08-06 2021-12-02 アルデイラ セラピューティクス， インコーポレイテッド 多形化合物およびその使用
CN111053777A (zh) * 2018-10-16 2020-04-24 正大天晴药业集团股份有限公司 伊布替尼的药物组合物及其应用
US11786518B2 (en) 2019-03-26 2023-10-17 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
WO2020223685A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
CN110272417B (zh) * 2019-06-18 2021-07-13 五邑大学 2-甲基-1,8-萘啶类化合物及其制备方法与应用
CN110305128B (zh) * 2019-07-31 2021-08-24 桂林医学院 5-氨基苯并[b][1,8]萘啶类化合物的制备方法和应用
JP2023526016A (ja) * 2020-05-13 2023-06-20 アルデイラ セラピューティクス， インコーポレイテッド 医薬製剤およびその使用
WO2025031970A1 (en) 2023-08-04 2025-02-13 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Drug combinations for treatment of diseases associated with tyrosine kinase receptor activation
WO2025106760A1 (en) * 2023-11-16 2025-05-22 Erx Pharmaceuticals Corporation Intranasal formulations of celastrol

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2799944A1 (en) * 2010-05-20 2011-11-24 University Of Rochester Methods and compositions related to modulating autophagy
US20120087915A1 (en) * 2010-06-03 2012-04-12 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
US20120071497A1 (en) * 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
TW201441234A (zh) * 2013-01-23 2014-11-01 Merck Sharp & Dohme Ｂｔｋ抑制劑
JP2016512549A (ja) * 2013-03-14 2016-04-28 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ阻害剤及びｃｙｐ３ａ４阻害剤の組み合わせ
MX369503B (es) * 2013-04-08 2019-11-11 Pharmacyclics Llc Combinaciones que comprenden ibrutinib y abt-199 para tratar trastornos proliferativos de células b y métodos de uso de las mismas.

Also Published As

Publication number Publication date
US20170354655A1 (en) 2017-12-14
EP3220912A1 (en) 2017-09-27
EP3220912A4 (en) 2018-06-20
BR112017010262A2 (pt) 2018-07-03
HK1243929A1 (zh) 2018-07-27
TW201628622A (zh) 2016-08-16
WO2016081460A1 (en) 2016-05-26
AU2015350136A1 (en) 2017-05-25
CN106999495A (zh) 2017-08-01
JP2017533944A (ja) 2017-11-16
CA2966542A1 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
MX2017006464A (es) Combinaciones de inhibidor de tlr e inhibidor de tirosina cinasa de bruton.
MX2017001656A (es) Combinaciones de inhibidor de tirosina cinasa de bruton y usos de estas.
PH12015502161A1 (en) Therapeutic compounds and compositions
MX2021013118A (es) Compuestos polifluorados que actuan como inhibidores de la tirosina cinasa de bruton.
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
MD4733B1 (ro) Anticorpi anti-TIGIT
MX2017002271A (es) Composiciones y metodos para el tratamiento de trastornos neurologicos.
EA201692204A1 (ru) Композиции и способы модулирования экспрессии фактора комплемента b
MX2017015226A (es) Compuestos alqueno tetrasustituidos y su uso.
WO2016044189A8 (en) Methods of treating cancer using pd-1 axis binding antagonists and il-17 binding antagonists
MX2015010921A (es) Compuestos de carbazol utiles como inhibidores de bromodominio.
EA201791516A1 (ru) Способы комбинированного лечения злокачественных опухолей
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
MX377593B (es) Composiciones para usar en el tratamiento de cáncer renal.
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
MY201580A (en) Use of ezh2 inhibitor combined with btk inhibitor in preparing drug for treating tumor
MX2017006022A (es) Inhibicion de ornitina aminotransferasa con analogos gaba para el tratamiento de carcinoma hepatocelular.
MX373409B (es) Composiciones para fibras de queratina.
BR112017009265A2 (pt) apilimode para uso no tratamento do câncer colorretal
MX2017000306A (es) Metodos para tratar hipotension.
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
MX2019000677A (es) Células miméticas de células b.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine